Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 12, 2025
Discovery & Translation

Pain targets in ion channel pathways: an Innovation Distillery spotlight

Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Dec 10, 2024
Politics, Policy & Law

Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast

Plus: KCC2 activation nears inflection point
BioCentury | Dec 6, 2024
Product Development

KCC2 activation nears inflection point

Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
BioCentury | Oct 31, 2024
Finance

Axonis advancing KCC2 program with $115M series A

BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Aug 13, 2024
Management Tracks

Lyell, Juno veteran Albertson becomes Caribou’s CMO

Plus: 10x names CCO, CFO and updates from Ovid, Cerevance, Fore, Atavistik, Velia, SpyBiotech, Telomir, Sernova and Holoclara
BioCentury | May 20, 2022
Emerging Company Profile

Iama: treating autism by restoring chloride homeostasis

The Italian newco is selectively inhibiting NKCC1 to restore chloride regulation while avoiding side effects of non-selective inhibitors
BioCentury | May 13, 2022
Data Byte

Distillery spotlight on Italian innovation

Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Jan 4, 2022
Deals

Company Quick Takes: TandemAI seeded with $25M

Plus Sutro and Tasly deal, Sirnaomics raises and more
BioCentury | Dec 3, 2021
Distillery Therapeutics

Enhancing SLC12A5 activity to treat refractory neonatal seizures

BioCentury | Dec 3, 2021
Distillery Therapeutics

Targeting CTNND2 phosphorylation for neuropathic pain

Items per page:
1 - 10 of 17